Haleon is a consumer health company that sells branded over-the-counter (OTC) health products across pharmacies, drug stores, grocery retailers, and e-commerce. Haleon's portfolio spans six categories: Oral Health (~31% of revenue), Pain Relief (~23%), Respiratory Health (~17%), Vitamins, Minerals & Supplements or VMS (~15%), Digestive Health (~9%), and Therapeutic Skin Health (~4%). Key brands include Sensodyne and parodontax in Oral Health; Panadol, Advil, and Voltaren in Pain Relief; Theraflu, Robitussin, and Flonase in Respiratory Health; and Centrum and Caltrate in VMS. Haleon's business model is built on selling branded products at a premium to generic alternatives, with pricing power supported by clinical evidence and healthcare professional recommendation. Dentists, pharmacists, and doctors recommending Haleon's products — particularly Sensodyne — create a flywheel of trial and consumer loyalty. Haleon invests heavily in advertising and promotion (A&P ran at ~20.5% of revenue in FY25) to sustain brand equity and support innovation launches. Geographically, North America (~35% of revenue), EMEA & LatAm (~42%), and APAC (~23%) are the three reporting segments. India and China are Haleon's two highest-priority growth markets, with Haleon taking full ownership of its China OTC joint venture in 2025. Haleon's growth strategy focuses on closing the gap between consumers who suffer from a condition and those who actively treat it, launching premium product variants, and expanding access to lower-income consumers in emerging markets through affordable pack sizes.